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ABSTRACT 
Two new series of 2-{1-[(substitutedphenyl)-hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one  and  (1H-
perimidin-2-yl)-[(substitutedphenyl)-hydrazono]-acetic acid ethyl ester were prepared by coupling the diazonium salt of 
aniline and its derivatives with 2-(2-oxo-2-phenyl-ethylidene)-5,5-diphenyl-imidazolidin-4-one or ethyl 3-dimethylamino-2-
(1H-perimidin-2-yl)-propenoate in ethanolic sodium hydroxide solution. The structures of all the newly synthesized 
compounds were confirmed by spectral (IR, 
1
H NMR, mass) spectra , and X-ray crystallographic and elemental analyses. 
Also, the azo-hydrazone tautomerism of these compounds was discussed. In addition, all the newly synthesized 
compounds were screened for their antibacterial and antifungal activity and the results obtained indicated that some of 
these compounds exhibited excellent activity.  
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INTRODUCTION  
In recent years, arylazo derivatives of various heterocyclic systems have been the subject of intense research by 
organic chemists [1] and dye manufactures [2]. These colouring matters were found useful in the fields of material 
sciences and theoretical chemistry [3]. For example, many of such azo dyes have been extensively used as dyes in 
various fields such as dyeing of textile fibers, coloured plastics, biological-medical studies and advanced applications in 
organic synthesis [4]. Recently, applications of such colouring materials to high technology have been attracting much 
attention. Dyes are used in various fields such as printing, electronic photography, color formers, liquid crystal displays, 
laser technology, data storage and solar energy conversion [5]. In addition, some of such dyes have found use as non-
linear optical (NLO) materials. They have potential use in optical communications, information processing, frequency 
doubling and integrated optics [6]. In the light of these findings and as a part of our comprehensive program directed for 
synthesis and elucidation of the tautomeric structures of arylazo-heterocycles [7-15], it was interesting to study herein the 
synthesis of two new series of 2-{1-[(substitutedphenyl)-hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-
one  and  (1H-Perimidin-2-yl)-[(substitutedphenyl)-hydrazono]-acetic acid ethyl ester which have not been reported hitherto. 
Our interest in such azo derivatives is to elucidate their tautomeric structure prior exploring their utility. Since each of such 
dyes can has one or more of the six tautomeric forms 5A-F or three tautomeric forms 10A-C depicted in Schemes 2 and 3. 
The knowledge of the actual tautomeric form(s) of azo dyes in solution and the solid phase is a quite important factor for 
the industrial and biological applications of azo dyes. Also, the antimicrobial activity of the newly synthesized compounds 
was evaluated,based on the previous reports which indicated that compounds containing imidazole, perimidine and 
hydrazone moieties have interesting biological activity such as antimicrobial [16-19], analgesic [20], anti-inflammatory [21] 
and anti-cancer [22,23] activities.  
Experimental  
Materials  
Melting points were determined on a Gallenkamp apparatus and are uncorrected. IR spectra were recorded in potassium 
bromide using Perkin Elmer FTIR 1650 and Pye-Unicam SP300 infrared spectrophotometers. 
1
H NMR spectra were 
recorded in deuterated DMSO-d6 using a Varian Gemini 200 NMR spectrometer. Mass spectra were recorded on a 
GCMS-QP 1000 EX Shimadzu and GCMS 5988-A HP spectrometers. Electronic absorption spectra were recorded on 
Perkin–Elmer Lambada 40 spectrophotometer. Elemental analyses were carried out at the Microanalytical Laboratory of 
Cairo University, Giza, Egypt. Antimicrobial activity was carried out at the Regional Center for Mycology and 
Biotechnology at Al-Azhar University, Cairo, Egypt.  
Crystallographic analysis  
The crystals were mounted on a glass fiber. All measurements were performed on an ENRAF NONIUS FR 590. The data 
were collected at a temperature of 25 
o
C using the ω scanning technique to a maximum of a 20 of 22.986
o
. The structure 
was solved by direct method using SIR 92 and refined by full-matrix least squares. Non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms were located geometrically and were refined isotropically. 
Crystal data 
For compound 5f: C29H21ClN4O2, M = 492.95, Monoclinic, a = 8.6867(3) Å, b = 25.8621(8) Å, c = 11.0795(3) Å, v = 
2483.55(13) Å
3
, α = 90.00°, β = 93.820(2)°,  γ = 90.00° , space group: P 1 21/n 1, Z=4,  Dx = 1.318 g/cm3, 15481 
reflections  measured, θmax = 66.64°.  Figure 1 illustrates the structure as determined [24]. 
2-(2-oxo-2-phenyl-ethylidene)-5,5-diphenyl-imidazolidin-4-one (3)  
A solution of compound 2 (1.93 g, 5 mmol) in diphenyl ether (10 ml) was heated in an oil bath at 200– 210 ºC for 10 min, 
then cooled. To the cold mixture was added ether where a white solid product precipitated. After complete precipitation, 
the solid product was collected, washed with ether and crystallized from ethanol to give 3 mp > 300 ºC [25]. 
Synthesis of ethyl 3-dimethylamino-2-(1H-perimidin-2-yl)-propenoate (7) 
A mixture of 6 [26] (2.64 g, 10 mmol) and dimethylformamide-dimethylacetal (1.2 g, 10 mmol)  in dry toluene (15 mL) was 
refluxed for 5 hrs. After cooling, the precipitate was collected by filtration and crystallized from dioxane as red solid, (89% 
yield), mp 270-272 ºC; IR (KBr) νmax  3225 (NH), 1710 (C=O), 1554 (C=N) cm
-1
; 
1
H NMR (DMSO-d6) δ 1.33 (t, J = 7 Hz, 
3H, CH3), 2.85, 2.90 (2s, 6H, 2CH3), 4.24 (q, J = 7 Hz, 2H, CH2), 6.80-8.43 (m, 6H, ArH), 8.72 (s, 1H, =CH), 10.82 (s, 1H, 
NH). MS m/z (%) 310 (M
+
+1, 20), 309 (M
+
, 24), 263 (56), 192 (44), 57 (100), 56 (48). Anal. Calcd. for C18H19N3O2 (309.36): 
C, 69.88; H, 6.19; N, 13.58. Found: C, 69.69; H, 6.02; N, 13.38% 
Coupling reaction of compounds 3, 6 and 7 with arenediazonium salts: 
General procedure: To a stirred solution of the appropriate compounds 3, 6 or 7 (10 mmol) in ethanol (50 ml) was added 
sodium hydroxide (0.4 g, 10 mmol) and the mixture was cooled in an ice bath to 0–5 ºC. To the resulting solution, while 
being stirred, was added dropwise over a period of 20 min the solution of the appropriate arenediazonium chloride which 
prepared as usual by diazotizing the respective aniline (10 mmol) in hydrochloric acid (6 M, 6 ml) with sodium nitrite (1 M, 
10 ml). The whole mixture was then left in a refrigerator overnight. The precipitated solid was collected, washed with water 
and finally crystallized from the appropriate solvent to give the respective hydrazones 5a-j and azo compounds 10a-i, 
respectively. The physical constants of the products 5a-j and 10a-i together with their spectral data are depicted bellow: 
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2-{1-[(4-Methoxyphenyl)hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one (5a) 
Yellow solid, (85% yield), mp > 300 ºC (Ethanol); IR (KBr) νmax 3447, 3298 (2NH), 1734, 1637 (2C=O), 1585 (C=N) cm
-1
; 
1
H NMR (DMSO-d6) δ 3.57 (s, 3H, OCH3), 7.34-7.86 (m, 19H, ArH), 10.54 (s, 1H, NH), 11.77 (s, 1H, NH). MS m/z (%) 488 
(M
+
, 15), 473 (19), 400 (21), 354 (90), 353 (100), 334 (25), 324 (21), 307 (21), 293 (23), 248 (25), 206 (22), 198 (22), 165 
(35), 153 (26), 105 (26), 77 (82). Anal. Calcd. for C30H24N4O3 (488.54): C, 73.76; H, 4.95; N, 11.47. Found: C, 73.59; H, 
4.78; N, 11.21% 
2-{1-[(4-Methylphenyl)hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one (5b) 
Yellow solid, (80% yield), mp 290-292 ºC (Ethanole/Dioxane); IR (KBr) νmax 3445, 3298 (2NH), 1731, 1636 (2C=O), 1581 
(C=N) cm
-1
; 
1
H NMR (DMSO-d6) δ 2.49 (s, 3H, CH3), 7.35-7.86 (m, 19H, ArH), 10.54 (s, 1H, NH), 11.74 (s, 1H, NH). MS 
m/z (%) 473 (M
+
+1, 13), 472 (M
+
, 20), 414 (17), 368 (20), 354 (100), 316 (17), 307 (12), 294 (22), 307 (21), 294 (22), 272 
(15), 244 (24), 221 (56), 182 (39), 176 (16), 165 (33), 153 (10), 147 (15), 114 (22), 105 (68), 73 (22). Anal. Calcd. for 
C30H24N4O2 (472.54): C, 76.25; H, 5.12; N, 11.86. Found: C, 76.04; H, 5.31; N, 11.67% 
 2-{1-[(3-Methylphenyl)hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one (5c) 
Yellow solid, (79% yield), mp > 300 ºC (Ethanol); IR (KBr) νmax 3444, 3298 (2NH), 1734, 1636 (2C=O), 1585 (C=N) cm
-1
; 
1
H NMR (DMSO-d6) δ 2.29 (s, 3H, CH3), 7.35-7.86 (m, 19H, ArH), 10.54 (s, 1H, NH), 11.79 (s, 1H, NH). MS m/z (%) 472 
(M
+
, 9), 354 (80), 276 (13), 249 (43), 234 (26), 221 (34), 181 (20), 167 (44), 165 (44), 146 (23), 105 (96), 77 (100). Anal. 
Calcd. for C30H24N4O2 (472.54): C, 76.25; H, 5.12; N, 11.86. Found: C, 76.10; H, 5.03; N, 11.72%. 
2-{1-(Phenylhydrazono)-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one (5d) 
Yellow solid, (88% yield), mp 240-242 ºC (Ethanol);  IR (KBr) νmax 3441, 3296 (2NH), 1733, 1636 (2C=O), 1585 (C=N) cm
-
1
; 
1
H NMR (DMSO-d6) δ 7.39-7.83 (m, 20H, ArH), 10.60 (s, 1H, NH), 11.77 (s, 1H, NH). MS m/z (%) 458 (M
+
, 6), 457 (9), 
354 (22), 325 (23), 277 (14), 249 (25), 221 (30), 182 (33), 165 (45), 146 (15), 128 (20), 105 (61), 77 (100). Anal. Calcd. for 
C29H22N4O2 (458.51): C, 75.97; H, 4.84; N, 12.22. Found: C, 75.69; H, 4.65; N, 12.14%. 
 2-{1-[(3-Chlorophenyl)hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one (5e) 
Orange solid, (75% yield), mp 116-118 ºC (Ethanol); IR (KBr) νmax 3427, 3312 (2NH), 1736, 1627 (2C=O), 1525 (C=N) cm
-
1
; 
1
H NMR (DMSO-d6) δ 7.21-7.55 (m, 19H, ArH), 11.16 (s, 1H, NH), 11.84 (s, 1H, NH). MS m/z (%) 495 (M
+
+2, 10), 494 
(M
+
+1, 29), 493 (M
+
, 43), 366 (100), 323 (27), 354 (38), 288 (17), 260 (12), 234 (20), 194 (2), 182 (22), 165 (26), 127 (22), 
105 (88), 77 (53). Anal. Calcd. for C29H21ClN4O2 (492.96): C, 70.66; H, 4.29; N, 11.37. Found: C, 70.52; H, 4.15; N, 
11.14%. 
2-{1-[(4-Chlorophenyl)hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one (5f) 
Yellow solid, (83% yield), mp 210-212 ºC (Ethanol); IR (KBr) νmax 3312 (2NH), 1734, 1635 (2C=O), 1530 (C=N) cm
-1
; 
1
H 
NMR (DMSO-d6) δ 7.16-7.91 (m, 19H, ArH), 11.15 (s, 1H, NH), 11.84 (s, 1H, NH). MS m/z (%) MS m/z (%) 495 (M
+
+2, 2), 
494 (M
+
+1, 3), 493 (M
+
, 6), 492 (6), 417 (9), 366 (71), 260 (15), 234 (18), 182 (24), 165 (39), 127 (20), 105 (85), 77 (100). 
Anal. Calcd. for C29H21ClN4O2 (492.96): C, 70.66; H, 4.29; N, 11.37. Found: C, 70.48; H, 4.10; N, 11.18% 
2-{1-[(3-Nitrophenyl)hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one (5g) 
Orange solid, (68% yield), mp 186-188 ºC (Ethanol); IR (KBr) νmax 3434, 3220 (2NH), 1743, 1647 (2C=O), 1532 (C=N) cm
-
1
; 
1
H NMR (DMSO-d6) δ 7.25-7.85 (m, 19H, ArH), 11.25 (s, 1H, NH), 11.92 (s, 1H, NH). MS m/z (%) 503 (M
+
, 39), 502 
(26), 474 (3), 411 (3), 366 (65), 323 (17), 288 (10), 260 (9), 234 (12), 165 (19), 105 (100), 77 (65). Anal. Calcd. for 
C29H21N5O4 (503.51): C, 69.18; H, 4.20; N, 13.91. Found: C, 69.04; H, 4.09; N, 13.76%. 
2-{1-[(4-Nitrophenyl)hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one (5h) 
Dark yellow solid, (83% yield), mp > 300 ºC (Ethanol/Dioxane); IR (KBr) νmax 3437, 3299 (2NH), 1738, 1636 (2C=O), 1572 
(C=N) cm
-1
; 
1
H NMR (DMSO-d6) δ 7.16-8.25 (m, 19H, ArH), 10.54 (s, 1H, NH), 11.92 (s, 1H, NH). MS m/z (%) 503 (M
+
, 
16), 366 (36), 354 (33), 323 (11), 249 (14), 234 (14), 182 (23), 165 (30), 105 (81), 77 (100). Anal. Calcd. for C29H21N5O4 
(503.51): C, 69.18; H, 4.20; N, 13.91. Found: C, 68.99; H, 4.12; N, 13.83%. 
2-{1-[(4-acetylphenyl)hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one (5i) 
Yellow solid, (91% yield), mp 260-262 ºC (Ethanol); IR (KBr) νmax 3462, 3264 (2NH), 1744, 1672, 1644 (3C=O), 1536 
(C=N) cm
-1
; 
1
H NMR (DMSO-d6) δ 2.49 (s, 3H, COCH3), 7.16-8.00 (m, 19H, ArH), 11.34 (s, 1H, NH), 11.83 (s, 1H, NH). 
MS m/z (%) 500 (M
+
, 8), 499 (6), 354 (65), 325 (18), 249 (27), 234 (19), 221 (24), 206 (14), 182 (31), 165 (34), 145 (11), 
105 (72), 77 (100). Anal. Calcd. for C31H24N4O3 (500.55): C, 74.38; H, 4.83; N, 11.19. Found: C, 74.17; H, 4.65; N, 
11.03%. 
2-{1-[(4-Ethoxycarbonylphenyl)hydrazono]-2-oxo-2-phenyl-ethyl}-5,5-diphenyl-3,5-dihydro-imidazol-4-one (5j) 
Yellow solid, (82% yield), mp 234-236 ºC; IR (KBr) νmax 3431, 3303 (2NH), 1734, 1729, 1636 (3C=O), 1525 (C=N) cm
-1
; 
1
H 
NMR (DMSO-d6) δ 1.30 (t, J = 7 Hz, 3H, CH3), 4.29 (q, J = 7 Hz, 2H, CH2), 7.16-7.98 (m, 19H, ArH), 10.55 (s, 1H, NH), 
11.73 (s, 1H, NH). MS m/z (%) 530 (M
+
, 7), 366 (15), 354 (54), 325 (14), 249 (18), 234 (16), 221 (19), 206 (11), 182 (29), 
165 (35), 138 (8), 105 (73), 77 (100). Anal. Calcd. for C32H26N4O4 (530.57): C, 72.44; H, 4.94; N, 10.56. Found: C, 72.18; 
H, 4.76; N, 10.50%. 
Ethyl (1H-Perimidin-2-yl)-[(4-methoxyphenyl)-hydrazono]-acetate (10a) 
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Brown solid, (88% yield), mp 192-194 ºC; IR (KBr) νmax 3429, 3112 (2NH), 1740 (C=O) cm
-1
; 
1
H NMR (DMSO-d6) δ 1.34 (t, 
J = 7 Hz, 3H, CH3), 3.72 (s, 3H, OCH3), 4.31 (q, J = 7 Hz, 2H, CH2), 6.69-7.46 (m, 10H, ArH), 10.80 (s, 1H, NH), 12.45 (s, 
1H, NH).  MS m/z (%) 389 (M
+
+1, 13), 388 (30), 135 (26), 122 (100), 107 (36), 77 (15). Anal. Calcd. for C22H20N4O3 
(388.42): C, 68.03; H, 5.19; N, 14.42. Found: C, 67.86; H, 4.95; N, 14.19%. 
Ethyl (1H-Perimidin-2-yl)-[(4-methylphenyl)-hydrazono]-acetate (10b) 
Dark green solid, (90 % yield), mp 224-226 ºC (Ethanol); IR (KBr) νmax  3425, 3145 (2NH), 1739 (C=O) cm
-1
; 
1
H NMR 
(DMSO-d6) δ 1.25 (t, J = 7 Hz, 3H, CH3), 2.32 (s, 3H, CH3), 4.54 (q, J = 7 Hz, 2H, CH2), 6.82-7.41 (m, 10H, ArH), 10.85 (s, 
1H, NH), 12.49 (s, 1H, NH). MS m/z (%) 373 (M
+
+1, 20), 372 (M
+
, 37), 371 (23), 208 (33), 255 (30), 91 (100), 77 (30). 
Anal. Calcd. for C22H20N4O2(372.42): C, 70.95; H, 5.41; N, 15.04. Found: C, 70.84; H, 5.25; N, 15.18%. 
Ethyl (1H-Perimidin-2-yl)-[(3-methylphenyl)-hydrazono]-acetate (10c) 
Brown solid, (79% yield), mp 178-180 ºC (Ethanol); IR (KBr) νmax 3411, 3210 (2NH), 1739 (C=O) cm
-1
; δ 1.31 (t, J = 7 Hz, 
3H, CH3), 2.25 (s, 3H, CH3), 4.40 (q, J = 7 Hz, 2H, CH2), 7.05-7.59 (m, 10H, ArH), 10.39 (s, 1H, NH), 11.98 (s, 1H, NH). 
MS m/z (%) 373 (M
+
+1, 3), 372 (M
+
, 11), 273 (100), 208 (39), 181 (47), 79 (15), 77 (29). Anal. Calcd. for 
C22H20N4O2(372.42): C, 70.95; H, 5.41; N, 15.04. Found: C, 70.90 H, 5.19; N, 15.07%. 
Ethyl (1H-Perimidin-2-yl)-(phenylhydrazono)-acetate (10d) 
Brown solid, (82 % yield), mp 162-164 ºC (Ethanol); IR (KBr) νmax 3415, 3100 (2NH), 1747 (C=O) cm
-1
; 
1
H NMR (DMSO-
d6) δ 1.33 (t, J = 7 Hz, 3H, CH3), 4.37 (q, J = 7 Hz, 2H, CH2), 6.95-7.73 (m, 11H, ArH), 11.30 (s, 1H, NH), 12.46 (s, 1H, 
NH).  MS m/z (%) 359 (M
+
+1, 15), 358 (M
+
, 50), 194 (25), 193 (100), 105 (35), 77 (70). Anal. Calcd. for C21H18N4O2 
(358.39): C, 70.38; H, 5.06; N, 15.63. Found: C, 70.17; H, 5.20; N, 15.46%. 
Ethyl (1H-Perimidin-2-yl)-[(4-chlorophenyl)-hydrazono]-acetate (10e) 
Raddish brown solid (72 % yield), mp 180-182 ºC (Ethanol/Dioxane); IR (KBr) νmax 3425, 3215 (2NH), 1739 (C=O) cm
-1
; 
MS m/z (%) 393 (M
+
+1, 11), 392 (M
+
, 38), 346 (25), 222 (64), 221 (46), 193 (100), 77 (20), 76 (11) Anal. Calcd. for 
C21H17ClN4O2 (392.84): C, 64.21; H, 4.36; N, 14.26. Found: C, 64.05; H, 4.19; N, 14.04%. 
Ethyl (1H-Perimidin-2-yl)-[(3-nitrophenyl)-hydrazono]-acetate (10f) 
Brick red solid (72% yield), mp 208-210 ºC (Ethanol/Dioxane); IR (KBr) νmax 3421, 3254 (2NH), 1725 (C=O) cm
-1
; 
1
H NMR 
(DMSO-d6) δ 1.32 (t, J = 7 Hz, 3H, CH3), 4.30 (q, J = 7 Hz, 2H, CH2), 7.21-7.98 (m, 10H, ArH), 11.12 (s, 1H, NH), 12.49 (s, 
1H, NH). MS m/z (%) 404 (M
+
+1, 15), 403 (M
+
, 35), 402 (19), 373 (13), 191 (56), 79 (17), 65 (100), 57 (25), 56 (35). Anal. 
Calcd. for C21H17N5O4 (403.39): C, 62.53; H, 4.25; N, 17.36. Found: C, 62.34; H, 4.48; N, 17.18%. 
Ethyl (1H-Perimidin-2-yl)-[(4-nitrophenyl)-hydrazono]-acetate (10g) 
Dark brown solid, (78% yield), mp 204-206 ºC (Ethanol/Dioxane); IR (KBr) νmax 3435, 3190 (2NH), 1739, (C=O) cm
-1
; 
1
H 
NMR (DMSO-d6) δ 1.31 (t, J = 7 Hz, 3H, CH3), 4.32 (q, J = 7 Hz, 2H, CH2), 7.19-8.27 (m, 10H, ArH), 11.58 (s, 1H, NH), 
12.21 (s, 1H, NH).  MS m/z (%) 403 (M
+
+1, 15), 402 (M
+
, 39), 194 (24), 193 (100), 77 (10), 65 (37). Anal. Calcd. for 
C21H17N5O4 (403.39): C, 62.53; H, 4.25; N, 17.36. Found: C, 62.49; H, 4.16; N, 17.30%. 
 Ethyl (1H-Perimidin-2-yl)-[(4-acetylphenyl)-hydrazono]-acetate (10h) 
Dark green solid, (81% yield), mp 168-170 ºC (Ethanol/Dioxane); IR (KBr) νmax 3418, 3297 (2NH), 1732, 1686 (2C=O) cm
-
1
; 
1
H NMR (DMSO-d6) δ 1.32 (t, J = 7 Hz, 3H, CH3), 2.37 (s, 3H, OCH3), 4.33 (q, J = 7 Hz, 2H, CH2), 6.63-8.01 (m, 10H, 
ArH), 11.58 (s, 1H, NH), 12.09 (s, 1H, NH).  MS m/z (%) 401 (M+1, 11), 400 (54), 399 (36), 193 (100), 192 (76), 180 (20), 
78 (32), 77 (31), 65 (21). Anal. Calcd. for C23H20N4O3 (400.43): C, 68.99; H, 5.03; N, 13.99. Found: C, 68.82; H, 5.16; N, 
13.78%. 
Ethyl (1H-Perimidin-2-yl)-[(4-ethoxycarbonylphenyl)-hydrazono]-acetate (10i) 
Dark red solid, (80% yield), mp 166-168 ºC (Ethanol/Dioxane); IR (KBr) νmax 3423, 3118 (2NH), 1739, 1712 (2C=O) cm
-1
; 
MS m/z (%) 431 (M
+
+1, 17.4), 430 (M
+
, 40), 429 (26), 194 (36), 193 (100), 192 (62), 78 (28), 77 (34). Anal. Calcd. for 
C24H22N4O4(430.46): C, 66.97; H, 5.15; N, 13.02. Found: C, 66.82; H, 5.02; N, 12.89%. 
Agar diffusion well method to determine the antimicrobial activity: 
The microorganism inoculums were uniformly spread using sterile cotton swab on a sterile petri dish malt extract agar (for 
fungi) and nutrient agar (for bacteria). One hundred ML of each sample was added to each well (6 mm diameter holes cut 
in the agar gel, 20 mm agar from one another). The systems were incubated for 24-48 h at 37 ºC (for bacteria) and at 28 
ºC (for fungi). After incubation, the micro-organisms growth was observed. Inhibition of the bacterial and fungal growth 
were measured in mm. Tests were performed in triplicate [27]. 
Results and discussion  
The starting ketene aminal 3 was prepared by reaction of the thione 1 with phenacyl bromide in aqueous sodium 
hydroxide to give 2-[(benzoylmethyl)thio]imidazolin-4-one 2, then, thermal heating of compound 2 in diphenyl ether at 200-
210 ºC afforded the ketene aminal 3 in good yield via extrusion of sulfur (Scheme 1). It is worth mentioning that the 
structure of compound 3 is consistent with the recent article [25] which reporting the synthesis of ketene aminal 3 via the 
Eschenmoser coupling reaction. 
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Scheme 1 
Coupling of compound 3 with diazotized aniline and its derivatives 4a-j in aqueous ethanol in the presence of sodium 
hydroxide afforded the respective arylazo derivatives 5a-j (Scheme 2). The mass spectra of the latter products revealed 
the molecular ion peaks at the expected m/z values and their elemental analysis data are consistent with their assigned 
structure. As shown in Scheme 2, compounds 5 may have one or more of six possible tautomeric structures A-F. Of these 
forms, structure 5A seems to be the forms of choice as they are consistent with their electronic absorption of compounds 
5. For example, like typical hydrazones [28,29], the electronic absorption spectra of 5 in dioxane revealed in each case 
two characteristic absorption bands in the regions λmax 393-331 and 334-229 nm (Table 1). Furthermore, the electronic 
spectrum of 5d, taken as typical example of the series studied, was recorded in solvents of different polarities. The spectra 
obtained showed little, if any, shift (Table 1) and the small shifts found in λmax of 5d in different solvents are due to solute-
solvent interaction. In agreement with this conclusion is the observation that the spectra of arylhydrazones derived from 
the reaction of quinones with N-alkyl-N-phenylhydrazine, unlike those of o- and p- hydroxyazo compounds, are largely 
independent of the solvent polarity [29]. This finding excludes the other tautomeric forms B-F (Scheme 2).  Other 
conclusive evidence for elucidation of the actual tautomeric structure 5A was obtained from the X-ray crystallographic 
analysis of compound 5f which illustrated in Figure 1. The selected bond lengths and bond angles of structure 5Af are 
depicted in Table 2 [24]. 
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Scheme 2 
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Table 1. UV Spectral data of compounds 5a-j in dioxane 
Compd. no.   max (log ) nm 
5a 332 (3.24), 300 (3.52) 
5b 332 (4.03), 229 (5.11) 
5c 331 (4.20), 229 (5.0) 
5d* 333 (4.70), 255 (3.28) 
5e 376 (4.48), 249 (4.16) 
5f 384 (3.51), 333 (3.62) 
5g 382 (4.15), 229 (3.66) 
5h 393 (3.49), 333 (3.67) 
5i 388 (3.19), 334 (3.90)  
5j 384 (3.67), 334 (3.89) 
*) 
Solvent max (log ): acetone: 333 (4.87), 254 (3.61); acetic acid: 339 (4.56), 238 (3.21);  cyclohexane: 309 (3.21), 238 
(4.05); ethanol 335 (4.85), 246 (4.45) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. ORTEP crystal structure of compound 5Af. 
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Table 2 
Selected bond lengths and bond angles in the ORTEP figure of compound 5f in the crystal. The crystallographic 
numbering does not reflect systematic numbering. 
 
 
 
 
 
 
 
In conjunction to our interest in the synthesis of new bioactive hydrazone derivatives [7-15], herein we reported the coupling reaction 
of the enaminone 7 with diazotized anilines giving the respective arylazo derivatives 10a-i (Scheme 3). Enaminone 7 was prepared 
by condensation of the ketene aminal 6 [26] with DMF-DMA in dry toluene under reflux. The structure of the enaminone 7 was 
established on the basis of spectral data and elemental analyses. For example, its 
1
H NMR spectrum exhibited the characteristic 
signals for the enaminone moiety at δ 8.72, 2.90 and 2.85 ppm assigned for the  olefinic =CH and the two methyl protons 
of –N(CH3)2 group in addition to the expected signals assigned for NH, aromatic and ester protons. Coupling of the latter 
enaminone 7 with diazotized anilines gives the respective arylazo derivatives 10a-i. On the basis of elemental analyses, IR, 
1
H 
NMR, and UV spectra (see Experimental), the isolated products were assigned structure 10. The formation of the products 
(10a-i) is assumed to take place via Japp-Klingemann reaction with elimination of dimethylformamide from the 
intermediate 9 to afford the product 7 as shown in Scheme 3.  In addition, the assigned structure for the products 10 was 
further confirmed by an alternative method for their synthesis. Thus, reaction of compound 6 with arendiazonium salts in 
ethanolic sodium hydroxide at 0-5 ºC afforded products which are typical in all respects (mp., mixed mp. and IR) with 
products 10. 
 Compounds 10 can exist in one or more of the three tautomeric forms 10A-C (Scheme 3). Of these three forms, the 
tautomeric form 10C seems to be the actual form for the studied compounds as it is consistent with their electronic 
absorption spectra, IR and 
1
H NMR spectra. For example, like typical azo-compounds [15] the electronic absorption 
spectra of 10a-i in dioxane revealed, in each case two characteristic absorption bands in the regions λmax 537-501 and 
396-362 nm (Table 3) and the electronic spectra of compound 10d, taken as a typical example of the series prepared, in 
different solvents exhibited little, if there is any, solvent dependence (Table 3). Also,  their  IR spectra revealed in each 
case two NH and carbonyl absorption bands  in the regions 3435-3411, 3297-3100 and 1747-1725 cm
-1
, respectively. The 
1
H NMR spectra are characterized by the two singlet signals assignable to two NH protons at δ 10.80-11.58 and 11.98-
12.49 ppm. These findings indicated that the isolated products exist in the tautomiric form 10C. 
Bond length, Å Bond length, Å Angle  (ω) 
N1-N2, 1.3061 N4-C17, 1.3604 C15-C7-C8, 120.22 
N2-C7, 1.3217 C15-N4, 1.3797 N2-N1-C4, 122.19 
C4-N1,  1.3973 N3-C16, 1.4654 N2-C7-C8, 116.74 
O2-C8,  1.2312 C15-N3, 1.2939 N3-C15-N4, 113.58 
C7-C8, 1.4759 N1-H1, 0.86 C15-N3-C16, 108.04 
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Scheme 3. Synthesis of compounds 10a-i 
 
Table 3. UV Spectral data of compounds 10a-i in dioxane 
Compd. no.   max (log ) nm 
10a 501 (4.19), 395 (3.97) 
10b 503 (3.96), 383 (4.54) 
10c 501 (4.14), 381 (3.67) 
10d* 505 (4.09), 362 (3.48) 
10e 521 (4.86), 383 (3.94) 
10f 506 (4.97), 377 (4.67) 
10g 515 (4.84), 363 (4.50) 
10h 537 (4.09), 396 (4.31) 
10i 523 (4.45), 386 (4.18) 
*) 
Solvent max (log ): acetone: 508 (3.05), 376 (3.68); cyclohexane: 500 (3.09), 375 (3.11); ethanol: 502 (3.29), 359 (3.10); 
DMF: 502 (3.11), 359 (4.31).  
 
 
    ISSN 2321-807X 
2702 | P a g e                                                   S e p t e m b e r  0 7 ,  2 0 1 4  
Biological Screening 
Anti-microbial activity 
In vitro anti-microbial screening of the tested compounds 3, 5 and 10 was carried out using four fungal strains, including 
Aspergillus fumigatus (AF), Syncephalastrum racemosum (SR) Geotricum candidum (GC) and Candida albicans (CA) and 
four bacteria species, including Gram positive bacteria, straphylococcus Pneumonia (SP) and Bacillus stubtilis (BS), Gram 
negative bacteria, Pseudomonas aeruginosa (PA) and Escherichia coli (EC). The reference drugs used for comparison 
are commonly applied antibiotics such as Amphotericin B, Ampicillin and Gentamicin (See Table 4). Preliminary anti-
microbial activity for the tested compounds 3, 5 and 10 indicate that compound 3 showed weak to mild activity aganist all 
used microorganisms, except fungus SR and Gram negative bacteria PA. Among compounds 5, the compound 5a has 
high potency aganist most of the tested fungi and bacteria species. 
On the other hand,  the results obtained for products 10 indicate that all these compounds have mild to zero activity ganist 
the used microorganisms. Compound 10g has high potency aganist fungus AF and Gram postive bacteria GC, SA, BS 
and Gram negative bacteria EC, whereas compound 10a has mild activity aganist fungi AF and GC and Gram postive 
bacteria SA and BS. Moreover, the results depicted in Table 4 indicate that compounds 10f and 10i exhibited no activity 
against fungi PI and CA and Gram negative bacteria PA and they have high to mild activity  against fungi species AF and 
GC and Gram postive bacteria SA, BS and Gram negative bacteria EC. Compounds 10b, 10c and 10e have no fungal and 
bacteria activity. 
 
Table 4. Preliminary anti-microbial activity for tested compounds 3, 5 and 10 
Compd  
No.  
Fungi  Gram positive 
bacteria  
Gram negative 
bacteria  
AF  
 
SR GC  CA  
SP  BS  PA  EC  
3  11.2  
(±0.44)  
N.A. 12.9 
(±0.44)  
10.4  
(±0.58) 
12.6  
(±0.27) 
13.9  
(±0.14) 
N.A. N.A.  
5a  20.3  
(±0.44)  
N.A.  22.4 
(±0.58)  
19.6  
(±0.37  
20.2  
(±0.44)  
22.3  
(±0.58)  
13.8 
(±0.37)  
16.8  
(±0.58)  
5b  10.2  
(±0.58)  
N.A. 12.6 
(±0.44)  
9.3 
(±0.63)  
11.4  
(±0.44)  
12.3 
(±0.25)  
N.A. N.A.  
5c  16.3 
(±0.44)  
N.A. 17.2 
(±0.25)  
15.3 
(±0.48)  
17.8  
(±0.67)  
19.2  
(±0.44)  
N.A. 13.4 
(±0.58)  
5d  11.6  
(±0.44)  
N.A.  12.7 
(±0.58)  
13.2  
(±0.63)  
15.6  
(±0.44)  
15.9  
(±0.44)  
N.A. 12.6 
(±0.58)  
5e  18.3  
(±0.44)  
N.A.  19.2 
(±0.58)  
18.4  
(±0.44)  
18.4  
(±0.37)  
20.2  
(±0.37)  
N.A. 15.3 
(±0.44)  
5f  17.3  
(±0.58)  
N.A. 18.3 
(±0.44)  
16.0  
(±0.37)  
16.7  
(±0.37)  
19.3  
(±0.44)  
N.A. 14.3  
(±0.58)  
5h  14.2  
(±0.58)  
N.A. 15.7 
(±0.58)  
13.1  
(±0.37)  
15.6  
(±0.44)  
17.2 
 (±0.58)  
N.A. 15.3  
(±0.44)  
10a  10.3  
(±0.58)  
N.A.  N.A. 12.4  
(±0.63)  
13.6  
(±0.58)  
14.9  
(±0.58)  
N.A. N.A. 
10b  N.A  N.A  N.A. N.A  N.A  N.A  N.A. N.A  
10c  N.A  N.A  N.A. N.A  N.A  N.A  N.A. N.A  
10d  N.A  N.A  N.A. N.A  13.3  
(±0.58)  
12.6  
(±0.44)  
N.A. N.A.  
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10e  N.A  N.A  N.A. N.A  N.A  N.A  N.A. N.A  
Amphotericin 
B 
23.7 
(±0.10) 
19.7  
(±0.2) 
28.7  
(±0.20) 
25.4  
(±0.1)  
N.A. N.A. N.A. N.A. 
Ampicillin  N.A. N.A. N.A. N.A. 23.8  
(±0.2)  
32.4 
(±0.30) 
N.A. N.A. 
Gentamicin  N.A. N.A. N.A. N.A. N.A. N.A. 17.3 
(±0.1)  
19.9  
(±0.30)  
 
Table 4.  Preliminary anti-microbial activity for tested compounds 
Compd  
No.  
Fungi  Gram positive 
bacteria  
Gram negative  
bacteria  
AF  
 
SR GC  CA  
SP  BS  PA  EC  
10f  14.9  
(±0.58)  
N.A.  N.A. 17.3  
(±0.58) 
16.9  
(±0.63)  
19.3 
(±0.67)  
N.A. 11.3  
(±0.44)  
10g  17.3  
(±0.58)  
N.A.  N.A. 22.4 
(±0.58)  
19.6  
(±0.58)  
22.5  
(±0.44)  
N.A. 14.6  
±0.44  
10i  16.9  
(±0.15)  
N.A. N.A. 19.9 
(±0.26)  
18.1  
(±0.44)  
20.9  
(±0.58)  
N.A. 12.2  
(±0.13)  
Amphotericin 
B 
23.7 
(±0.10) 
19.7  
(±0.2) 
28.7  
(±0.20) 
25.4  
(±0.1)  
N.A. N.A. N.A. N.A. 
Ampicillin  N.A. N.A. N.A. N.A. 23.8  
(±0.2)  
32.4 
(±0.30) 
N.A. N.A. 
Gentamicin  N.A. N.A. N.A. N.A. N.A. N.A. 17.3 
(±0.1)  
19.9  
(±0.30)  
 
Conclusion 
In this paper we described an efficient and simple method for preparation of two new hydrazone series 5 and 10. The 
method summarized in coupling reaction of 2-benzoylmethylene-5,5-diphenyl-3,5-dihydroimidazol-4-one 3 and enaminone 
7 with arenediazonium salts in ethanolic sodium hydroxide solution at low temperature (0-5 ºC). The electronic absorption 
spectra (UV/vis) together with the other spectral methods (IR, 
1
H NMR, mass) indicated that products 5 exist in the 
tautomeric hydrazone form 5A. Further confirmation for the tautomeric form 5A was based on the X-ray crystallographic 
analysis which recorded for one typical example for series 5. In a similar manner and based on electronic absorption 
spectra together with the data obtained from spectral (IR, 
1
H NMR, mass) analyses of products 10, it was found that the 
predominant tautomeric form is 10c. In addition, the biological activity for products 5 and 10 were screened and the results 
obtained revealed that compounds 5 and 10g have promising potency against most the used fungal and bacteria species. 
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